These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 17551496)
1. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Bozionelou V; Vamvakas L; Pappas P; Agelaki S; Androulakis N; Kalykaki A; Nikolaidou M; Kentepozidis N; Giassas S; Marselos M; Georgoulias V; Mavroudis D Br J Cancer; 2007 Jul; 97(1):43-9. PubMed ID: 17551496 [TBL] [Abstract][Full Text] [Related]
2. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. Saridaki Z; Pappas P; Souglakos J; Nikolaidou M; Vardakis N; Kotsakis A; Marselos M; Georgoulias V; Mavroudis D Cancer Chemother Pharmacol; 2009 Dec; 65(1):121-8. PubMed ID: 19415279 [TBL] [Abstract][Full Text] [Related]
3. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors. Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S Oncology; 2005; 69(6):463-9. PubMed ID: 16374040 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203 [TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695 [TBL] [Abstract][Full Text] [Related]
6. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline. Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947 [TBL] [Abstract][Full Text] [Related]
7. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419 [TBL] [Abstract][Full Text] [Related]
8. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381 [TBL] [Abstract][Full Text] [Related]
9. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Tas F; Guney N; Derin D; Aydiner A; Topuz E Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors. Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V Oncology; 2002; 62(3):216-22. PubMed ID: 12065868 [TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711 [TBL] [Abstract][Full Text] [Related]
13. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660 [TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622 [TBL] [Abstract][Full Text] [Related]
15. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review. Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103 [TBL] [Abstract][Full Text] [Related]
16. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience. Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192 [TBL] [Abstract][Full Text] [Related]
17. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Brana I; Calles A; LoRusso PM; Yee LK; Puchalski TA; Seetharam S; Zhong B; de Boer CJ; Tabernero J; Calvo E Target Oncol; 2015 Mar; 10(1):111-23. PubMed ID: 24928772 [TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587 [TBL] [Abstract][Full Text] [Related]
19. A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. Bozionelou V; Kalbakis K; Vamvakas L; Agelaki S; Androulakis N; Kalykaki A; Georgoulias V; Mavroudis D Cancer Chemother Pharmacol; 2009 Sep; 64(4):785-91. PubMed ID: 19159931 [TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors. Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]